The device, known as Contivue in Europe, comprises the eye implant through which Susvimo is delivered, plus four ancillary devices to initially fill, insert, refill and remove the implant if required. Susvimo (ranibizumab injection) 100 mg/mL remains under review in Europe for the treatment of neovascular age-related macular degeneration (nAMD).
Contivue provides continuous delivery of a customized ranibizumab formulation directly to the eye with immediate and predictable durability. Roche specifically engineered its port delivery platform for use with the customized formulation for gradual release over time. The company also has more molecules in the pipeline for potential use with the delivery platform for continued growth and expansion.
Patients receive the implant in their eye during a one-time, outpatient procedure. Refills occur once every six months using a specifically designed needle that introduces the therapeutic directly into the device.
“Susvimo offers people living with nAMD the opportunity to maintain their vision with as few as two treatments per year,” said Dr. Levi Garraway, PhD, Roche’s chief medical officer and head of global product development. “Moreover, this sustained delivery brings substantial long-term clinical benefits, as demonstrated by the seven years of follow-up data from the LADDER study.”
Susvimo originally received FDA approval in 2021, but Roche voluntarily recalled the therapy the following year before reintroducing it to the market in 2024.
